Searched for
SCHERING PLOUGH
IPAB's verdict on Roche's Hepatitis C drug patent may impact MerckThe IPAB revoked Roche's patent for Pegasys on grounds that the process of pegylation did not enhance the efficacy of the drug.- Merck scouting for Indian partnersMerck is looking at partnerships with Indian firms that have their own R&D and manufacturing capability, says chief executive designate Ken...
- Relocation triggers exits at Merck armAround 50 executives quit MSD, the Indian arm of Merck & Co, in the past few months — most opted out due to the company’s decision to reloc...
- Merck to take buyout route to grow hereThe world’s second-biggest drugmaker, Merck & Co, is looking at acquisitions and alliances with local firms to scale up its business in Ind...
- HC rejects Fulford plea against United Biotech, Oscar RemediesWhen a trademark is derived from the common generic name, no single proprietor can claim absolute monopoly in such name or trade mark, rule...
- Merck plans to shift India head office to MumbaiUS-based drugmaker Merck plans to relocate headquarter of its India office to Mumbai, making it the third major pharma company to shift key...
- Merck Q1 sales rise but profit fall on chargesDrugmaker Merck & Co. says double-digit sales growth for a half-dozen of its top medicines fueled a 7 percent jump in first-quarter sales.
- Pfizer, Merck to cut 1,700 jobs following mergersCombined, Pfizer and Wyeth plan to cut about 20,000 jobs, or 15 percent of their combined staff in the future. Top 10 Paymasters | Intervie...
- US court to hear Glenmark's patent dispute on Aug 19Glenmark Pharmaceuticals’ patent challenge against Schering Plough’s cholesterol-lowering drug Zetia will come up for hearing in the US dis...
- Glenmark gets first nod for Zetia genericGlenmark Pharmaceuticals has got tentative approval from the USFDA for the generic version of Schering Plough and MSP Singapore Company LLC...
- Merck buys Schering-Plough in $41.1b cash-&-stock dealUS-based Merck & Co is acquiring Schering-Plough for $41.1 billion in a cash-and-stock deal, to create a $47 billion drug major.
- Merck buys Schering-Plough for $41 bn to access new drugsUS-based Merck & Co on Monday said it is acquiring Schering Plough for $41.1 bn in a cash-and-stock deal to create a $42-bn drug major.
- Pharmaceutical giants Merck, Schering-Plough announce mergerUS pharmaceutical giants Merck and Schering-Plough announced their merger early on Monday in a stock-and-cash transaction valued 41.1 billi...
- Lupin gains 4% over drug patent settlementDrug maker Lupin rose over 4 per cent after the firm said it had settled a patent litigation with US-based Schering-Plough Corp relating to...
- Lupin declares litigation settlement with Schering-PloughLupin Ltd has settled all ongoing Hatch-Waxman litigation relating to desloratadine tablets, the generic version of Schering-Plough's Clari...
- FDA rejects Schering drug to reverse anesthesiaGovernment regulators dealt a major setback to Schering-Plough Corp, rejecting a highly anticipated drug designed to help patients recover ...
- Cancer fears may spark decline in Vytorin salesSales of Merck & Co and Schering-Plough Corp’s Vytorin, falling after data earlier this year questioned its effectiveness against a cheaper...
- Global pharma cos explore contract research in IndiaA new chapter is being added to the Indian pharma story. Leading global pharma and biotechnology firms, such as Schering-Plough, Bristol-My...
- Schering-Plough, Sanofi set sights on Bristol-MyersBristol-Myers Squibb, which fired its chief executive officer this week, may be targeted for takeover by Schering-Plough or French drugmake...
- Goldman buys 7% in Fulford India for Rs 13 crGoldman Sachs’ private equity fund has bought 7% in Fulford India, an affiliate of the US-based pharma firm, Schering-Plough, for Rs 13 cro...
Load More- Merck to take buyout route to grow here
